BBI-4000, 15%
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperhidrosis
Conditions
Hyperhidrosis
Trial Timeline
Mar 8, 2016 → Oct 4, 2016
NCT ID
NCT02682238About BBI-4000, 15%
BBI-4000, 15% is a phase 2 stage product being developed by Botanix Pharmaceuticals for Hyperhidrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02682238. Target conditions include Hyperhidrosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02682238 | Phase 2 | Completed |
Competing Products
14 competing products in Hyperhidrosis
Other Products from Botanix Pharmaceuticals
Sofpironium Bromide, 15% + VehiclePhase 3
69
Sofpironium Bromide Gel, 15% + VehiclePhase 3
69
Sofpironium Bromide Gel, 5% + Sofpironium Bromide Gel, 15%Phase 3
69
BBI-4000 gel, 5% + BBI-4000 gel, 10% + BBI-4000 gel, 15% + Vehicle (Placebo)Phase 2
44
BBI-4000 Gel, 5% + BBI-4000 Gel, 10% + BBI-4000 Gel, 15% + VehiclePhase 2
44